Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/04/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 16/04/21 | Issuer sale | Controller/Auditor | 88,423 | 0.1899% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +0.33% | +1.37% | +64.03% | +119.11% | 55.63B | |
| +0.82% | +15.05% | +79.93% | +84.34% | 52.25B | |
| +1.36% | +0.36% | -14.06% | -14.69% | 23.07B | |
| -1.04% | +7.91% | +1.61% | +419.24% | 22.41B | |
| -0.18% | +7.20% | +32.16% | -14.07% | 17.32B | |
| -1.10% | +4.00% | +28.70% | -34.51% | 15.94B | |
| -3.35% | +8.96% | +132.20% | +290.18% | 13.47B | |
| +2.89% | +5.51% | +27.11% | +181.45% | 13.77B | |
| +1.31% | +0.53% | +28.62% | - | 12.43B | |
| Average | +0.11% | +4.78% | +42.26% | +128.88% | 25.14B | |
| Weighted average by Cap. | +0.26% | +5.13% | +48.50% | +120.17% |
Employees
51
